期刊文献+

钠-葡萄糖共转运蛋白2抑制剂抗足细胞损伤机制研究进展

Research progress on mechanism of sodium-glucose cotransporter 2 inhibitors against podocyte damage
原文传递
导出
摘要 慢性肾脏病是一个全球性的公共卫生问题,可进展为终末期肾脏病。足细胞损伤是多种肾小球疾病常见的病理类型,蛋白尿的发生可随足细胞数量的减少而增加。足细胞损伤的治疗仍受到病因复杂、免疫治疗副作用大、非免疫抑制靶向治疗起步晚等诸多限制。近年来,关于钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)在慢性肾脏病中的作用机制研究越来越广泛而深入,但以足细胞为靶点的研究报道仍较少。本文综述SGLT2i抗足细胞损伤机制,以期为SGLT2i在治疗足细胞损伤相关性疾病中的应用提供更充分的理论支持。 Chronic kidney disease is a global public health problem,which can progress to end-stage kidney disease.Podocyte injury is a common pathological type of various glomerular diseases,and the incidence of proteinuria can increase with the decrease of podocyte number.The treatment of podocyte injury is still limited by complex etiology,significant side effects of immunotherapy,and late initiation of targeted non-immunosuppressive therapy.In recent years,the research on the mechanism of sodium-glucose cotransporter 2 inhibitors(SGLT2i)in chronic kidney disease had become increasingly extensive and in-depth,but there were still few reports on targeting podocytes.In this paper,the mechanism of SGLT2i against podocyte injury is reviewed,which provides a more sufficient theoretical foundation for the application of SGLT2i in the treatment of podocyte injury-related diseases.
作者 环薇 李潇 洪文娟 罗晓菲 成家茂 HUAN Wei;LI Xiao;HONG Wen-juan;LUO Xiao-fei;CHENG Jia-mao(Clinical Medical College of Dali University,Dali YUNNAN 671003,China;Department of Nephrology,the First Affiliated Hospital of Dali University,Dali YUNNAN 671013,China;Department of Human Anatomy,Basic Medical College of Dali University,Dali YUNNAN 671003,China)
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2024年第9期646-650,共5页 Chinese Journal of New Drugs and Clinical Remedies
基金 2023年度云南省教育厅科学研究基金研究生项目(2023Y0973) 大理市2022年科技计划项目(2022KBG059) 大理大学第一附属医院杰出中青年人才项目(DFYJC-202108)。
关键词 钠-葡萄糖共转运蛋白2抑制剂 肾功能衰竭 足细胞 慢性肾脏病 sodium-glucose cotransporter 2 inhibitors kidney failure podocytes chronic kidney disease
  • 相关文献

参考文献3

二级参考文献19

共引文献225

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部